The firm said the funding will support the launch of its miniaturized ELISA platform, which reduces the time and sample volume required for such assays.
The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.
Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.